Good MorningEquity markets tried to build on the previous week's strength, but the gains were fleeting. The S&P 500 closed with a small daily gain but aligned with recent highs. The move suggests a lack of momentum and increasing resistance to higher prices that may cap gains for the remainder of the summer. The CPI report was good but aligned with the outlook for FOMC rate cuts that are already priced into the market. There is a high risk that it will be a sell-the-news event, and a stock market price correction will soon follow.
The S&P 500 may not fall far. The outlook for earnings growth remains robust, and with interest rates set to drop, strength will bleed into a broader array of sectors. In this scenario, a market correction is a buy-the-dip opportunity leading to another multi-quarter rally for the index. Featured: Amazon coin set to soar 25X – starting July 22nd (True Market Insiders) 
|
Markets | | |
NVIDIA Corp. (NASDAQ: NVDA) continues to be one of the best-performing stocks in 2024. At a split-adjusted price of $129.71, NVDA stock is up 160% in 2024. However, NVIDIA’s coattails appear to be fairly short. The market growth is limited to a relatively narrow range of stocks, mostly in la... Read the Full Story |
|
From Our PartnersWith the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades...
In fact, it just detected a move happening this MONDAY. | | | | See here to see the full details. |
|
Markets | | |
The iShares Russell 2000 ETF (NYSE: IWM) experienced a significant breakout above multi-year resistance last week, sparked by the release of the CPI inflation data on Thursday. This move was one of the most eye-opening events of the week, drawing significant attention to small-cap stocks.
IWM's I... Read the Full Story |
|
Markets | | |
Ford Motor Company (NYSE: F) is navigating a significant transformation as the automotive sector transitions from gas power and embraces the electric vehicle (EV) future. This shift has led many investors and Ford Motor’s analyst community to wonder if now is the time to buy Ford Motor sto... Read the Full Story |
|
From Our PartnersWe’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable. | | | | Download your free report today! |
|
Tech | | |
International Gaming Technology PLC (NYSE: IGT) provides worldwide electronic gambling, gaming, and lottery products and services. It’s well known for providing most of the slot machines in Las Vegas in the pre-pandemic era. The company has expanded to include digital games through its Pla... Read the Full Story |
|
Markets | | |
Solid-state battery technology company QuantumScape Co. (NYSE: QS) stock awakened, jumping nearly 46% on news of a new agreement with PowerCo, a subsidiary of Volkswagen AG (OTCMKTS: VWAGY). QuantumScape received much hype and fanfare in 2021 regarding its solid-state lithium-metal battery techn... Read the Full Story |
|
From Our PartnersThis key unlocks a new pathway to wealth that has been kept hidden from you for decades.
In my new documentary I will provide you with all the details of this one-of-a-kind investment. | | | | Let me explain in this new documentary video |
|
Markets | | | British luxury fashion house Burberry said Monday it has appointed Joshua Schulman, formerly head of Michael Kors and Coach, as its new chief executive officer as the company warned it expected to record an operating loss in the first half of the year amid slumping retail sales. Burberry said Schulm... Read the Full Story |
|
Markets | | | UnitedHealth topped second-quarter forecasts but remains cautious about the year as it continues to eat costs from a massive cyberattack and deals with rising medical expenses.The health care giant on Tuesday said it was sticking with an earnings forecast for 2024 it first laid out last fall that in... Read the Full Story |
|
Markets | | | Macy's is terminating its monthslong buyout talks with two investment firms, citing a substandard offer and the lack of certainty over financing. In announcing the end of negotiations on Monday, Macy’s alleged that Arkhouse Management and Brigade Capital Management did not meet its request for infor... Read the Full Story |
|
Markets | | | Thailand’s prime minister has said that eligible businesses and individuals can register from August for digital cash handouts, a controversial program that will cost billions of dollars and is meant to boost the lagging economy Read the Full Story |
|
Markets | | | Goldman Sachs is posting a 150% jump in second quarter profits Monday, helped by a resurgence of dealmaking and underwriting that has revived investment banking after the slowdown of the previous couple years.The New York investment bank posted net earnings of $3.04 billion, $8.62 per share, compare... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. | Should I Buy Alnylam Pharmaceuticals Stock? ALNY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Sunday, February 16, 2025 at 1:49 PM.
Alnylam Pharmaceuticals Bull Case -
Alnylam Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock's future performance.
-
The recent price target set by Scotiabank at $300.00 suggests a potential upside of 16.98% from the current stock price of $256.45, which could attract investors looking for growth opportunities.
-
Several analysts have recently upgraded their ratings and price targets, with Barclays increasing their target to $329.00, reflecting confidence in the company's future prospects.
-
Alnylam Pharmaceuticals, Inc. has a solid market capitalization of $33.08 billion, which indicates a stable financial foundation and the ability to invest in research and development.
-
The company focuses on innovative therapeutics based on ribonucleic acid interference, positioning itself in a cutting-edge field of biopharmaceuticals that could lead to significant breakthroughs.
Alnylam Pharmaceuticals Bear Case -
The stock has experienced a decline of 3.2% recently, which may raise concerns about its short-term performance and market volatility.
-
Insider selling has been notable, with executives selling a total of 73,964 shares worth over $20 million in the last three months, which could signal a lack of confidence in the stock's near-term prospects.
-
Alnylam Pharmaceuticals, Inc. has a negative price-to-earnings ratio of -97.88, indicating that the company is not currently profitable, which can be a red flag for potential investors.
-
The company has a relatively high debt-to-equity ratio of 31.64, suggesting that it relies heavily on debt financing, which could pose risks if market conditions change.
-
Despite a strong pipeline, the biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new products to market successfully.
| | View Today's Stock Pick |
|
